Physical Sciences and Mathematics Commons^™

Heat Shock Protein 90: A Potential Therapeutic Target In Leukemic Progenitor And Stem Cells Harboring Mutant Bcr-Abl Resistant To Kinase Inhibitors, C Peng, Dongguang Li, L Shaoguang

Research outputs pre 2011

Development of drug resistance has become a major obstacle for tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and other cancers. The BCR-ABL-T315I mutant does not respond to clinically available TKIs, although some newly developed anti-BCR-ABL-T315I TKIs are now being tested in patients. TKIs transiently inhibit kinase activity of BCR-ABL, but do not reduce the level of the BCR-ABL protein. Elimination of mutant BCR-ABL protein would provide a new therapeutic strategy for treating Ph+ leukemia. We recently showed that inhibition of heat shock protein 90 (Hsp90) by a novel Hsp90 inhibitor, IPI-504, causes …